Nai Xili peptide and congestive heart failure in children.doc

 PAGE \* MERGEFORMAT 9 Nai Xili peptide and congestive heart failure in children 【Key Words】,,,,, congestive Nesiritide for children with congestive heart failure Congestive heart failure (congestive heart failure, CHF) is a common clinical syndrome, with ventricular remodeling, hemodynamics, and neurohormonal changes characterized by [1]. Cardiac natriuretic peptides, such as brain natriuretic peptide (brain natriuretic peptide, BNP) is a recent study compared the number of neuro-endocrine hormones. When the myocardial wall by pulling or pressure, the main production and secretion stimulated myocardial BNP. BNP could serve as a CHF diagnosis, effective monitoring, prognosis, risk stratification such as the effective symbol [2]. However, acute CHF, the body’s secretion of BNP amount insufficient to reverse the symptoms of CHF. Nai Xili peptide (nesiritide) for the recombinant human endogenous brain natriuretic peptide, a diuretic, the role of the natriuresis, but also can reduce pulmonary capillary wedge pressure, pulmonary artery pressure, right atrial pressure, systemic vascular resistance, increased cardiac index , stroke index and left ventricular ejection fraction [3,4], in August 2001 by the U.S. Food and Drug Administration approved for the treatment of acute decompensated CHF in clinical practice. In this paper, the pharmacological effects for the Naixi Li-peptide and its application in congestive heart failure in the therapeutic value, especially in the pediatric research in the field are reviewed. 1 Current treatment of heart failure At present, the treatment of heart failure drugs, including the following: angiotensin-converting enzyme inhibitors, β-receptor blockers, diuretics, inotropic drugs and vasodilators. Angiotensin-converting enzyme inhibitors improve the clinical symptoms and reduce re-admission rate, and improve the role of survival, but the main adverse events were cough (20%), symptomatic hypotension and rena